Endocrinology, Diabetes & Metabolism
Endocrinology
Clinical Trials
For information concerning ongoing clinical trials and patient eligibility, please contact:
- Karen Brezner, Study Coordinator
Division Administrator
Phone (352) 846-2234
Fax (352) 846-2231
E-mail breznka@medicine.ufl.edu
Pituitary Disorders
The overall goal of the proposed study is to use the model of combined testosterone and growth hormone deficiencies due to hypopituitarism to determine if replacement of testosterone and growth hormone. We propose to select men who have deficiencies of testosterone and growth hormone due to hypopituitarism and randomize them to receive either testosterone alone or testosterone plus growth hormone for two years (open enrollment).
The purpose of this study is to evaluate and safety and the effects of long term therapy with Humatrope. This is medication used to replace growth hormone (somatropin). Humatrope has been approved by the United States Food and Drug Administration (FDA) for use in people who have decreased levels of growth hormone (or growth hormone deficiency). In this study the effects of Humatrope will be compared in people who will and will not receive it. This study will last for 5 years during which time, you will be seen in clinic every 6 months, for a total of 11 visits (enrollment closed).
Acromegaly is a rare disease that occurs when the body is producing too much of a certain kind of hormone (a kind of body chemical), called growth hormone. It is usually caused by a benign (non‑cancerous) tumor in your pituitary gland. The purpose of this study is to assess the safety and effectiveness of long-term Somavert treatment of acromegaly.The study may provide valuable information about acromegaly and its treatment (open enrollment).
The aim of this trial is to assess whether SOM230 LAR has the potential to be a better treatment for patients with acromegaly than the currently available standard treatment Sandostatin® LAR. Therefore, in this trial, treatment with SOM230 LAR is compared to treatment with Sandostatin® LAR. (open enrollment)
SOM230 exhibits a unique binding profile with high affinity to four of the five known human somatostatin receptors. Researchers reported that SOM230 significantly inhibited ACTH release in two cultured human corticotroph adenoma cells. SOM230 may provide an alternative treatment for Cushing’s disease by inhibiting the release of ACTH, subsequently decreasing the amount of cortisol produced by adrenal glands. (open enrollment)